



PLAINTIFF TRIAL EXHIBIT
P-21442\_00001

## Fewer peaks and valleys

Smooth steady-state plasma levels compared with controlled-release (CR) morphine tablets q12h and q24h<sup>1</sup>





The clinical significance of pharmacokinetic data is unknown.

KADIAN® Capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

KADIAN® Capsules are not for use as a prn analgesic.

KADIAN® is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild or not expected to persist for an extended period of time. KADIAN® is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time.

Please see accompanying complete Prescribing Information.



### More flexibility with KADIAN Capsules

# The unique dosing flexibility of KADIAN® Capsules gives you more options with a morphine



Capsules are not shown at actual size.

- 8 dosing strengths—the most of any extended-release morphine 1,3,4
- Flexibility to dose q12h or q24h¹
- No immediate-release (IR) component
- Allows for titration in increments of 10 mg, with a low dose of 10 mg<sup>1</sup>
  - o In accordance with American Pain Society guidelines about low initial dosing<sup>5</sup>

Prescribe KADIAN® Capsules—Less pain for your patients. More options for you.

#### WARNING

KADIAN® contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. KADIAN® can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing KADIAN® in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.

KADIAN® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

KADIAN® Capsules are NOT for use as a prn analgesic.

KADIAN® 100 mg and 200 mg Capsules ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. Ingestion of these capsules or of the pellets within the capsules may cause fatal respiratory depression when administered to patients not already tolerant to high doses of opioids. KADIAN® CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.

### Safety considerations

Serious adverse reactions that may be associated with KADIAN® therapy in clinical use are those observed with other oral opioid analgesics and include: respiratory depression, respiratory arrest, apnea, circulatory depression, cardiac arrest, hypotension, and/or shock.

References: 1. KADIAN® [prescribing information]. Morristown, NJ: Actavis Elizabeth LLC; January 2008. 2. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain. 1997; 69(3):295-302. 3. AVINZA® [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; April 2008. 4. MS Contin® [prescribing information]. Stamford, CT: Purdue Pharma LP; August 2007. 5. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, IL: American Pain Society; 2003.

For further information, please visit www.KADIAN.com or call 1-888-496-3082.

Please see accompanying complete Prescribing Information.



1000

©2008 Actavis Elizabeth LLC. KADI8D0229C All rights reserved. Printed in USA

